Skip to main content
Kissei Pharmaceuticals announced 20 deaths related to receiving avacopan (Tavneos), a vasculitis drug sold by the firm i

Dr. John Cush RheumNow

2 months 1 week ago
Kissei Pharmaceuticals announced 20 deaths related to receiving avacopan (Tavneos), a vasculitis drug sold by the firm in Japan. Drug was released in June 2022, since its been given to ~8,500 pts. Avacopan safety is being reviewed by FDA with Amgen. https://t.co/ri0nROCL5U https://t.co/jbksrWMFwI
FDA has approved a dosing update for burosumab-twza (Crysvita, Kyowa Kirin) to allow for increased dose and frequency wh

Dr. John Cush RheumNow

2 months 1 week ago
FDA has approved a dosing update for burosumab-twza (Crysvita, Kyowa Kirin) to allow for increased dose and frequency when needed in adults with X-linked hypophosphatemia (XLH). https://t.co/EPyp6tDsaf https://t.co/1HEaQRk9BR
Goofy study of the month! (pub in JAMA!) RCT 170 adults w/ chronic LBP + MRI disc herniation found that amoxicillin-clav

Dr. John Cush RheumNow

2 months 1 week ago
Goofy study of the month! (pub in JAMA!) RCT 170 adults w/ chronic LBP + MRI disc herniation found that amoxicillin-clavulanate, 500 mg/125 mg bid x 3 mos did not improve pain at 3 or 12 mos (vs PBO). Whatha... https://t.co/njrw6itAP8 https://t.co/CW2ssNPxf1
Prospective study of 40 newly Dx, Tx-naïve RA pts starting MTX; Of serum cytokines tested, high baseline IL-6 & IL-

Dr. John Cush RheumNow

2 months 1 week ago
Prospective study of 40 newly Dx, Tx-naïve RA pts starting MTX; Of serum cytokines tested, high baseline IL-6 & IL-17 was assoc w/ nonresponse to MTX. Yet, still not good response biomarkers. TNF-α & GM-CSF did not assoc w/ MTX outcomes https://t.co/YIQKop9LMH https://t.co/XxwcRsKwoM
Israel study 264,858 pregnancies- 1st trimester NSAID exposure had no risk of congenital malformations (MCM). 8% exposed

Dr. John Cush RheumNow

2 months 1 week ago
Israel study 264,858 pregnancies- 1st trimester NSAID exposure had no risk of congenital malformations (MCM). 8% exposed vs unexposed: overall MCM 8.2% v 7%; aRR 0.99). MCMs not incr = MSK, CV, CNS, cleft palate, GI, GU, nonsignif MSM aRR from 0.77- 1.05 https://t.co/ytYhBFl44o https://t.co/1fq4D1KykM
ABA versus HCQ in Palindromic Rheumatism

Palindromic rheumatism may develop rheumatoid arthritis (RA) and could be an

Dr. John Cush RheumNow

2 months 1 week ago
ABA versus HCQ in Palindromic Rheumatism Palindromic rheumatism may develop rheumatoid arthritis (RA) and could be an at-risk population. A pilot trial compared abatacept (ABA) versus hydroxychloroquine and demonstrated ABA reduces RA development in a 2 year study. https://t.co/z0ptEYdhQj
APR: Fibromyalgia

Dr. Jack Cush reviews Fibromyalgia as part of the Advanced Practice Rheum video series.

https://t.

Dr. John Cush RheumNow

2 months 1 week ago
APR: Fibromyalgia Dr. Jack Cush reviews Fibromyalgia as part of the Advanced Practice Rheum video series. https://t.co/jq6dSXy6SU https://t.co/bDGRhhY2D9
Hydroxychloroquine (HCQ) is one of the most important drugs in rheumatology, especially for systemic lupus erythematosus (SLE). It reduces flares, organ damage, cardiovascular events, and pregnancy complications, and it improves survival. Yet many clinicians still prescribe HCQ as if body weight reliably predicts drug exposure. It does not.
In this week's RheumIQ quiz: An RA patient has a current or new cancer. With which cancer should you avoid/stop the use

Dr. John Cush RheumNow

2 months 1 week ago
In this week's RheumIQ quiz: An RA patient has a current or new cancer. With which cancer should you avoid/stop the use of a TNF inhibitor? See if you got it right at https://t.co/DTabBEfjj9 https://t.co/tVYUEjAPy3
Study of 305 newly Dx axSpA pts (age 38 yrs; 55% male, Dx delay 6yrs, 75% B27+). Clinical Dx, without Xray/imaging in

Dr. John Cush RheumNow

2 months 1 week ago
Study of 305 newly Dx axSpA pts (age 38 yrs; 55% male, Dx delay 6yrs, 75% B27+). Clinical Dx, without Xray/imaging in 12%, 5% developed sacroiliitis during 8 yr F/U. r-axSpA mostly male w/ ^CRP https://t.co/zGjb3uSkjP https://t.co/3bdGAvKXAm
Medical Economics reports only 18% MDs practiced in MD-owned settings, a new low. By Jan '26 hospitals or corporate empl

Dr. John Cush RheumNow

2 months 1 week ago
Medical Economics reports only 18% MDs practiced in MD-owned settings, a new low. By Jan '26 hospitals or corporate employment rose to 550,494 & independent MDs fell to 120,900 https://t.co/l0tt3yO9kt https://t.co/pkgmHFPjE1
Depression screening (PHQ-8) equally accurate in pts w/ & w/o chronic pain. Depression screening is not biased by ov

Dr. John Cush RheumNow

2 months 1 week ago
Depression screening (PHQ-8) equally accurate in pts w/ & w/o chronic pain. Depression screening is not biased by overlapping symptoms in depression and chronic pain. https://t.co/UWf97NDPAK https://t.co/7dvt35RT9E
Infectious Rheumatology (5.15.2026)

Dr. Jack Cush discusses his favorite journal articles from the past week on RheumN

Dr. John Cush RheumNow

2 months 1 week ago
Infectious Rheumatology (5.15.2026) Dr. Jack Cush discusses his favorite journal articles from the past week on RheumNow. https://t.co/MzqDykG78w https://t.co/z7BsADXo4x
Update on Multicentric Reticulohistiocytosis

Have you ever seen multicentric reticulohistiocytosis (MRH)? Don't worry,

Dr. John Cush RheumNow

2 months 1 week ago
Update on Multicentric Reticulohistiocytosis Have you ever seen multicentric reticulohistiocytosis (MRH)? Don't worry, it's a rare non-Langerhans cell histiocytosis condition characterized by papulonodular skin lesions and symmetric erosive polyarthritis, and it has only been https://t.co/koXOwktDgA
A Korean insurance claims data study showed children and adolescents diagnosed with uveitis have a 7-fold increased risk of developing an immune-mediated inflammatory disorder (IMID).
×